Cato Events Podcast

The U.S. government’s current strategy of trying to restrict the supply of opioids for nonmedical uses is not working. While government efforts to reduce the supply has reduced both the amount of legally manufactured prescription opioids and the number of opioid prescriptions, deaths from opioid-related overdoses are nevertheless accelerating. Research shows that the increase is due, in large part, to substitution of illegal heroin and fentanyl for the now harder-to-get prescription opioids. Attempting to reduce overdose deaths by doubling down on this approach will not produce better results. Policymakers can reduce overdose deaths and other harms stemming from nonmedical use of opioids and other dangerous drugs by switching to a policy of harm-reduction. Harm reduction has a success record that prohibition cannot match and involves a range of public health options.Unlike prohibition, harm-reduction strategies begin with the realistic and nonjudgmental premise that there has never been, and will never be, a drug-free society. Akin to the credo of the medical profession — “First, do no harm” — harm reduction seeks to avoid measures that exacerbate the harm that prohibition already inflicts on nonmedical users and seeks to focus on the goal of reducing deaths and the spread of disease from drug use.This conference, featuring clinical and research experts in epidemiology, public health, addiction treatment, and harm reduction, will examine the record of various harm-reduction modalities in the developed world and will consider their potential for ameliorating the problems caused by drug prohibition.

Hosted on Acast. See acast.com/privacy for more information.

The U.S. government’s current strategy of trying to restrict the supply of opioids for nonmedical uses is not working. While government efforts to reduce the supply has reduced both the amount of legally manufactured prescription opioids and the number of opioid prescriptions, deaths from opioid-related overdoses are nevertheless accelerating. Research shows that the increase is due, in large part, to substitution of illegal heroin and fentanyl for the now harder-to-get prescription opioids. Attempting to reduce overdose deaths by doubling down on this approach will not produce better results. Policymakers can reduce overdose deaths and other harms stemming from nonmedical use of opioids and other dangerous drugs by switching to a policy of harm-reduction. Harm reduction has a success record that prohibition cannot match and involves a range of public health options.Unlike prohibition, harm-reduction strategies begin with the realistic and nonjudgmental premise that there has never been, and will never be, a drug-free society. Akin to the credo of the medical profession — “First, do no harm” — harm reduction seeks to avoid measures that exacerbate the harm that prohibition already inflicts on nonmedical users and seeks to focus on the goal of reducing deaths and the spread of disease from drug use.This conference, featuring clinical and research experts in epidemiology, public health, addiction treatment, and harm reduction, will examine the record of various harm-reduction modalities in the developed world and will consider their potential for ameliorating the problems caused by drug prohibition.

Hosted on Acast. See acast.com/privacy for more information.

The U.S. government’s current strategy of trying to restrict the supply of opioids for nonmedical uses is not working. While government efforts to reduce the supply has reduced both the amount of legally manufactured prescription opioids and the number of opioid prescriptions, deaths from opioid-related overdoses are nevertheless accelerating. Research shows that the increase is due, in large part, to substitution of illegal heroin and fentanyl for the now harder-to-get prescription opioids. Attempting to reduce overdose deaths by doubling down on this approach will not produce better results. Policymakers can reduce overdose deaths and other harms stemming from nonmedical use of opioids and other dangerous drugs by switching to a policy of harm-reduction. Harm reduction has a success record that prohibition cannot match and involves a range of public health options.Unlike prohibition, harm-reduction strategies begin with the realistic and nonjudgmental premise that there has never been, and will never be, a drug-free society. Akin to the credo of the medical profession — “First, do no harm” — harm reduction seeks to avoid measures that exacerbate the harm that prohibition already inflicts on nonmedical users and seeks to focus on the goal of reducing deaths and the spread of disease from drug use.This conference, featuring clinical and research experts in epidemiology, public health, addiction treatment, and harm reduction, will examine the record of various harm-reduction modalities in the developed world and will consider their potential for ameliorating the problems caused by drug prohibition.

Hosted on Acast. See acast.com/privacy for more information.

The U.S. government’s current strategy of trying to restrict the supply of opioids for nonmedical uses is not working. While government efforts to reduce the supply has reduced both the amount of legally manufactured prescription opioids and the number of opioid prescriptions, deaths from opioid-related overdoses are nevertheless accelerating. Research shows that the increase is due, in large part, to substitution of illegal heroin and fentanyl for the now harder-to-get prescription opioids. Attempting to reduce overdose deaths by doubling down on this approach will not produce better results. Policymakers can reduce overdose deaths and other harms stemming from nonmedical use of opioids and other dangerous drugs by switching to a policy of harm-reduction. Harm reduction has a success record that prohibition cannot match and involves a range of public health options.Unlike prohibition, harm-reduction strategies begin with the realistic and nonjudgmental premise that there has never been, and will never be, a drug-free society. Akin to the credo of the medical profession — “First, do no harm” — harm reduction seeks to avoid measures that exacerbate the harm that prohibition already inflicts on nonmedical users and seeks to focus on the goal of reducing deaths and the spread of disease from drug use.This conference, featuring clinical and research experts in epidemiology, public health, addiction treatment, and harm reduction, will examine the record of various harm-reduction modalities in the developed world and will consider their potential for ameliorating the problems caused by drug prohibition.

Hosted on Acast. See acast.com/privacy for more information.

Justice John Paul Stevens’s majority opinion in Chevron v. Natural Resources Defense Council (1984) has become among the most hotly debated topics in legal circles. The “Chevron Doctrine,” which says that courts should defer to the interpretations of executive agencies on ambiguous statutes, divides scholars across ideological lines. Chevron’s growth from a “puny little precedent” into a landmark decision makes for an intriguing discussion about administrative agencies, judicial deference, and unintended consequences. What actually happened in Chevron v. NRDC? How much should courts defer to agencies’ reasonable interpretations of statutes? Is Chevron the ultimate legal example of “be careful what you wish for”? Administrative law experts discuss these topics and more in Chevron: Accidental Landmark, a documentary short from FedSoc Films. Join us for a screening of the film and a panel discussion about the past, present, and future of the Chevron Doctrine.

Hosted on Acast. See acast.com/privacy for more information.